+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 70Years +
All Genders
ID07020065

Study Comparing Reduced-Dose Carboplatin-Doublet Chemotherapy Plus Cemiplimab Versus Cemiplimab Alone in Older and Frail Patients With Metastatic NSCLC and Low PD-L1 Expression

Led by Swiss Cancer Institute · Updated on 2026-10-28

156

Participants Needed

18

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatment options for patients aged 70 and older with metastatic non-small cell lung cancer NSCLC who have lower than 50% PD-L1 expression and may be frail or in poor health. The study aims to compare the safety and effectiveness of reduced-dose chemotherapy combined with cemiplimab versus cemiplimab alone. This research addresses a gap in evidence for older and frail patients who often cannot tolerate standard chemotherapy doses well. Participants are randomly assigned to one of two groups one receives reduced-dose platinum-doublet chemotherapy combined with cemiplimab, while the other receives cemiplimab monotherapy. The chemotherapy regimens differ according to cancer histology and are given intravenously every three weeks for four cycles, followed by maintenance cemiplimab treatment for up to two years. Patients whose cancer progresses may switch from monotherapy to the combination treatment if suitable. Throughout the study, participants undergo regular imaging scans to assess tumor response every 6 to 12 weeks, along with quality-of-life questionnaires and geriatric assessments of physical function at set intervals. Researchers will monitor progression-free survival, overall survival, response rates, side effects, and overall treatment utility. The trial includes ongoing safety monitoring and aims to provide evidence to improve treatment strategies for older, vulnerable NSCLC patients.

CONDITIONS

Brief Title

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Research Team

G

Gisela Müller

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here